RespireRx Pharmaceuticals Inc (RSPI)

[apu_85]

The good news is that nobody is more impacted by dilution than current management so we are aligned there.

It's crazy there are only 95 common stockholders...

Here is info on their financing. They referenced $10-$14M for Sleep Apnea Phase 3 trial.

Financing our Platforms
We anticipate filing a Form 1-A with the SEC, which if qualified would enable the Company to engage in a Regulation A
offering (Reg A Offering). We provide no assurance that we will file a Form 1-A, or if filed that the Reg A Offering would be
qualified, or if qualified, would result in a financing on terms as to price per share or other securities offered, amount of funds raised or
other terms acceptable to the Company or at all. Our major challenge has been to raise substantial equity or equity-linked financing to
support research and development plans for our cannabinoid and neuromodulator platforms, while minimizing the dilutive effect to
pre-existing stockholders. At present, we believe that we are hindered primarily by our public corporate structure, our OTCQB listing,
and low market capitalization as a result of our low stock price. For this reason, the Company has effected an internal restructuring plan
through which our two drug platforms have been reorganized into separate businesses units, and may, in the future, be spun out into
subsidiaries.
We believe that by creating one or more subsidiaries to further the aims of Project ResolutionRx and Project EndeavourRx, it
may be possible, through separate finance channels, to optimize the asset values of each.
For a more detailed discussion of our Cannabinoid and Neuromodulator programs, see subsections I and II under Item 1 –
Business above.